Fresh Start, page-49

Possibly a bit of navel gazing in that boardroom at the moment.

Its coming to crunch time, and they are still trying to find data to support that their drug is working.

Remember that although ATL1102 is being trialed for non ambulant boys, its mode of operation should help ambulant boys as well. As prof V has stated previously.

So potentially huge market share of DMD. And DMD is just one very small subset of the addressable inflammation market.

We need the drug hitting arms and positive readouts. We are slowly treading in that direction.

This market cap provides huge upside potential for when the above happens.